Hikal Ltd has successfully completed a US Food and Drug Administration (US FDA) inspection at its Jigani facility in Bengaluru, Karnataka. The inspection, conducted from February 3 to February 7, 2025, resulted in six observations.
As a responsible and compliant pharmaceutical and life sciences company, Hikal Ltd is committed to addressing these observations promptly. The company will submit a detailed response to the US FDA within the stipulated timeframe, ensuring adherence to global regulatory standards.
In the meantime, Hikal Ltd.’s shares closed yesterday at ₹377.00, down from the opening price of ₹381.00. The stock hit a high of ₹381.00 and a low of ₹371.55 during the session. Hikal’s 52-week range stands between ₹260.30 and ₹464.75, reflecting significant volatility.
